Anti-Obesity Vaccine Research Recognized at Two International Vaccine Conferences

Braasch Biotech Invited to Present Pre-Clinical Results of Anti-Obesity Vaccine at Two International Vaccine Conferences

Online PR News – 18-March-2011 – – Garretson, South Dakota – Dr. Keith Haffer, President and CSO of Braasch Biotech LLC, has been invited to present results of the firm’s anti-obesity vaccines at two international vaccine conferences.
In April, Dr. Haffer will speak at the World Vaccine Congress 2011,in Washington DC. The topic of the paper, to be presented on April 14th, will be: Advancing the world's first immunization-based Growth Hormone (GH) and Insulin like Growth Factor-1 (IGF-1) treatments using novel second-generation Somatostatin vaccines.
In May Dr. Haffer will present data at the The Fourteenth Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases, in Baltimore Maryland. The title of the paper, to be presented on Monday, May 16th, will be: Treatment of Obesity by a Therapeutic Vaccination Approach.
“Braasch’s novel therapeutic treatment for obesity has not only gained attention in marketing reviews, but also within the scientific vaccine community” stated Keith N. Haffer, Ph.D., president of Braasch. “Our invitations to be asked to speak at conferences of this caliber are an honor for our firm.”
Braasch Biotech is executing a proactive strategy to continue to build and strengthen a diverse and competitive intellectual property portfolio that provides the company and its partners with a strong proprietary position in the therapeutic vaccine space. The company was recently issued its first US patent and has filed additional patents in the US and Europe for applications of its technologies for obesity, diabetes type 2, myocardial diseases and Rett Syndrome.

About Braasch Biotech LLC. Braasch Biotech, LLC is a privately preclinical-stage vaccine company that utilizes chimeric somatostatin proteins in optimized adjuvant systems for immunologically increasing endogenous Growth Hormone and Insulin-like Growth Factor-1 (IGF-1). The company is based in South Dakota with headquarters located in Garretson and laboratories in Sioux Falls.